Ligand Pharmaceuticals (LGND) Stock May Trade At A Discount On XOMA Royalty Deal

Ligand Pharmaceuticals has logged a very large 3 year share price gain, which naturally raises the question of whether that move is grounded in the cash the business can generate. With that kind of run on the board, the focus shifts to whether today’s market value lines up with the stream of cash flows investors now pay for.

• Over the past 3 years the stock has returned roughly 4.8x an initial investment, which puts a lot of weight on the assumption that future cash flows can support such a step up in market expectations.
• The acquisition of XOMA Royalty and the recent US$700m zero coupon convertible financing may support a larger royalty portfolio and greater financial flexibility, which can affect both the timing and stability of Ligand Pharmaceuticals’ future cash generation.
• If you'd rather focus on earnings, this one's for you. See why Ligand Pharmaceuticals's 30.0x P/E tells a different valuation story.

For investors, the debate is whether Ligand Pharmaceuticals’ current share price is adequately backed by the intrinsic value suggested by its Discounted Cash Flow (DCF) estimate of future cash flows.

If you want a broader watchlist of companies where valuation is anchored to cash generation, a focused screener of 35 high quality undervalued stocks can be a useful next step in your research.

Does Ligand Pharmaceuticals Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here values Ligand Pharmaceuticals on the cash it is expected to generate for shareholders. Latest twelve month free cash flow sits around $130.1m, and the projections build in growing free cash flow through the next decade as the royalty portfolio and pipeline mature.

Analysts see free cash flow in 2030 at a little over $300m. The second stage of the model assumes more moderate expansion beyond that point. Because those future streams are discounted back to today, the outcome is an estimated intrinsic worth that the model indicates is substantially above the current share price of $297.28. The acquisition of XOMA Royalty and the $700m zero coupon convertible raise help explain why the DCF can justify stronger long run cash generation than the market is currently pricing in. Find out what Ligand Pharmaceuticals could be worth using our Discounted Cash Flow (DCF) estimate.

The Ligand Pharmaceuticals Narrative: What Would Justify Today's Price?

Narratives for Ligand Pharmaceuticals pick up exactly where that valuation puzzle leaves off and spell out what kind of growth, margins and earnings profile would need to unfold for the stock to be worth materially more or less than today’s price, based on the scenarios shared on Simply Wall St’s Community page. Rather than a single multiple or model output, each narrative lays out the key assumptions behind its view of fair value so you can compare those expectations with actual results over time.

Bullish and bearish takes on Ligand Pharmaceuticals split around how durable the enlarged royalty engine really is once XOMA and new deals are fully in the mix.

Bull case: 14% undervalued

"Expansion of Ligand Pharmaceuticals’ high margin royalty portfolio through the completed XOMA Royalty acquisition, which adds more than 120 assets..."

Discover why this Narrative puts Ligand Pharmaceuticals at 14% undervalued.

Bear case: 11% overvalued

"The emphasis on continued dealmaking, with a target of US$150 million to US$250 million invested annually in new royalty opportunities, exposes Ligand to the risk that future transactions are completed at richer terms..."

Explore why this Narrative puts Ligand Pharmaceuticals at 11% overvalued.

One more Ligand Pharmaceuticals check that sits beyond the DCF math

Cash flows and scenarios only tell part of the story, because the people running Ligand Pharmaceuticals and the way their pay is structured can heavily influence how those projections play out over time. See who runs Ligand Pharmaceuticals and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com